Evidence map›Paper›PMID 39106415›Full record

ArticleRetinal cases & brief reports2025

MANAGEMENT OF PERIFOVEAL EXUDATIVE VASCULAR ANOMALOUS COMPLEX.

Maria Cristina Savastano, Claudia Fossataro, Gianni Gravina, Francesca Coccimiglio, Clara Rizzo, Stanislao Rizzo

Abstract readCase Reports
In one paragraph

Article in Retinal cases & brief reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maria Cristina SavastanoOphthalmology Unit, "Fondazione Policlinico Univesitario Agostino Gemelli, IRCCS", Rome, Italy.
Claudia FossataroOphthalmology Unit, "Fondazione Policlinico Univesitario Agostino Gemelli, IRCCS", Rome, Italy.
Gianni GravinaOphthalmology Unit, "Fondazione Policlinico Univesitario Agostino Gemelli, IRCCS", Rome, Italy.
Francesca CoccimiglioOphthalmology Unit, "Fondazione Policlinico Univesitario Agostino Gemelli, IRCCS", Rome, Italy.
Clara RizzoOphthalmic Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy ; and.
Stanislao RizzoOphthalmology Unit, "Fondazione Policlinico Univesitario Agostino Gemelli, IRCCS", Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo report a case of a patient with perifoveal exudative vascular anomalous complex (PEVAC) and to analyze morphologic and vascular changes by optical coherence tomography (OCT) and OCT angiography (OCTA) before and after treatment. MATERIALS AND

methodsThe authors reported a case that received multiple treatments for unresponsive effect to repeated aflibercept intravitreal injections, subthreshold micropulse laser therapy duty cycle 5%. At last, the focal full-dose yellow laser was performed.

resultsA 57-year-old male patient presented with best-corrected visual acuity (BCVA) of 20/50 in his right eye (RE). The fundoscopic evaluation, structural OCT, and OCTA deposed for a diagnosis of PEVAC. The patient underwent three aflibercept intravitreal injections in the RE. Because no changes were detected, the authors opted for multiple sessions of yellow subthreshold micropulse laser therapy duty cycle 5%; however, no signs of regression were registered. Only after a full-dose yellow laser, signs of edema regression were observed. Structural OCT B-scan showed complete restoration of retinal profile, in the absence of any intraretinal or subretinal fluid and PEVAC lesion, whereas the OCTA showed a slight flow deficit at the previous lesion site. CONCLUSION AND IMPORTANCE: The PEVAC treatment is still unknown. In their experience, the authors reported a case of multiple treatments for unresponsive effect to aflibercept intravitreal injections, subthreshold micropulse laser therapy duty cycle 5%. The focal full-dose yellow laser was the only effective treatment in this patient. The authors proposed the management to share the heterogeneous response at PEVAC entity.

Indexed as

Fovea CentralisLaser CoagulationReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinal DiseasesRetinal VesselsVascular MalformationsAngiogenesis InhibitorsFluorescein AngiographyFundus OculiHumansIntravitreal InjectionsMaleMiddle AgedTomography, Optical CoherenceVisual AcuityafliberceptAngiogenesis InhibitorsReceptors, Vascular Endothelial Growth FactorRecombinant Fusion Proteinsoptical coherence tomography, angiography (OCTA)optical coherence tomography (OCT)perifoveal exudative vascular anomalous complex (PEVAC)subthreshold micropulse laser (SMPL)

Identifiers

PMID39106415
PMCPMC12570618

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.